Actively Recruiting
Multicenter Randomized Study Comparing Cenegermin Eye Drops to Placebo for Healing Persistent Corneal Epithelial Defects
Led by Dompé Farmaceutici S.p.A · Updated on 2026-10-07
150
Participants Needed
77
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the safety and effectiveness of cenegermin eye drops to heal persistent corneal epithelial defects PCED, a condition where the cornea does not properly heal. This phase 3 clinical trial compares cenegermin with a placebo vehicle to see how well it induces complete healing after 4 weeks of treatment. The study is conducted across multiple centers with participants randomly assigned to groups, and both participants and researchers do not know who receives which treatment. Participants will receive either cenegermin or a placebo eye drop applied topically to the affected eye. The study includes three periods an initial 8-week treatment phase, followed by an 8-week extension treatment phase for continued evaluation, and finally a 24-week follow-up phase to monitor long-term outcomes. Participants are randomly assigned to one of the two groups, and the treatment is administered throughout these periods. During the study, participants will be regularly assessed to monitor corneal healing and safety. Measurements include the proportion of participants achieving complete healing at 4 and 8 weeks, changes in the size of the corneal defect, and monitoring of any adverse events up to week 40. Study visits and evaluations will track progress and safety over the total study duration, ensuring careful follow-up of all participants.
CONDITIONS
Brief Title
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
Research Team
D
Dompé farmaceutici S.p.A. Via Santa Lucia, 6, 20122 Milan (MI)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here